NurExone Biologic (TSXV:NRX) FCF Yield % : -14.44 (As of Mar. 04, 2025)

View and export this data going back to 2022. Start your Free Trial

What is NurExone Biologic FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, NurExone Biologic's Trailing 12-Month Free Cash Flow is C$-6.04 Mil, and Market Cap is C$41.83 Mil. Therefore, NurExone Biologic's FCF Yield % for today is -14.44%.

The historical rank and industry rank for NurExone Biologic's FCF Yield % or its related term are showing as below:

TSXV:NRX' s FCF Yield % Range Over the Past 10 Years
Min: -33.98 Med: 0 Max: 0
Current: -14.44

TSXV:NRX's FCF Yield % is ranked better than
50.07% of 1502 companies
in the Biotechnology industry
Industry Median: -14.475 vs TSXV:NRX: -14.44

NurExone Biologic's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.

NurExone Biologic FCF Yield % Historical Data

The historical data trend for NurExone Biologic's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NurExone Biologic FCF Yield % Chart

NurExone Biologic Annual Data

Trend

Dec21

Dec22

Dec23

FCF Yield %

-31.71

-28.85

NurExone Biologic Quarterly Data
	Mar21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Yield %	Get a 7-Day Free Trial									-38.46	-26.39	-18.23	-11.51	-15.09

Competitive Comparison of NurExone Biologic's FCF Yield %

For the Biotechnology subindustry, NurExone Biologic's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NurExone Biologic's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NurExone Biologic's FCF Yield % distribution charts can be found below:

* The bar in red indicates where NurExone Biologic's FCF Yield % falls into.

NurExone Biologic FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

NurExone Biologic's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-4.107	/	14.23375
	=	-28.85%

NurExone Biologic's annualized FCF Yield % for the quarter that ended in Sep. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-1.516	*	4	/	40.19469
	=	-15.09%

NurExone Biologic FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

NurExone Biologic FCF Yield % Related Terms

Thank you for viewing the detailed overview of NurExone Biologic's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

NurExone Biologic Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (TSXV:NRX) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

NRXBF:USA J90:Germany

Address

1 Adelaide St. East, Suite 801, Toronto, ON, CAN, M5C 2V9

Website

https://www.nurexone.com

NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.

Executives

James Angus Wilson (bilkstys-) Richardson

10% Security Holder, Director, Senior Officer

NurExone Biologic Headlines

No Headlines